Effect of Evolocumab on Progression of Coronary Disease in Statin-Treated Patients (GLAGOV Trial)

The GLAGOV (Global Assessment of Plaque Regression with a PCSK9 Antibody as Measured by IntraVascular Ultrasound) trial randomized 968 statin-treated patients to evolocumab or placebo and followed coronary atheroma by serial IVUS over 76 weeks.

Evolocumab reduced LDL-C from a median of 92.5 mg/dL to 36.6 mg/dL — levels approaching what Mendelian randomization studies have suggested as the biological optimum. At this degree of LDL-C reduction, 64% of patients in the evolocumab arm experienced plaque regression, versus 47% in the placebo arm. Overall atheroma volume decreased significantly in the evolocumab group and increased slightly in the placebo group.

The GLAGOV trial is pivotal for several reasons. First, it demonstrated that plaque regression is not simply a statin phenomenon — PCSK9 inhibition produces additional regression beyond maximal statin therapy. Second, the dose-response relationship between LDL-C achieved and plaque regression held at LDL-C levels below 25 mg/dL, suggesting there may be no lower threshold below which further reduction is futile. Third, the magnitude of plaque regression increased as achieved LDL-C decreased.

These findings, combined with the FOURIER and ODYSSEY Outcomes clinical event trials, establish evolocumab and alirocumab as agents with both mechanistic and clinical validation for aggressive LDL-C reduction in high-risk patients.

We rate the evidence strong. A landmark IVUS trial demonstrating that PCSK9 inhibition on top of statins achieves greater plaque regression than statins alone — establishing the mechanistic basis for aggressive combination lipid lowering.